Project seeks $6m injection
RENOWNED for its volatility worldwide, the biotechnology sector has again been enjoying a sustained pick-up over the past two months.
Local company Eastland Medical Systems is of the view that while the market remains tough, recent signs show the timing is right for new ventures.
The biotech sector has accounted for a significant proportion of recently announced market floats in the US and Eastland is also prepared to brave the times.
Eastland has announced an initial public offering, hoping to raise $6 million in time to list on the Australian Stock Exchange in January.
The company already has 70 per cent of the capital it needs to bring to market three retractable injection, infusion and blood-drawing devices, for which it has obtained exclusive production licences for Australasia.
The products are fully developed and contracts for outsourcing large-scale manufacturing are almost in place.
Eastland believes it has a strategic market advantage in that its add-on products are complementary to existing syringes and canulas.
The company is also convinced the products are more affordable, safer and easier to use than other products designed to prevent needlestick injuries.
Existing retractable syringes costing three times the value of the Eastland product have failed to prevent injury in some instances and are limited in application.
The company has welcomed Federal Government recognition and promised support for the introduction of safer products to prevent needle stick injury.
To read more, please Login below or
Subscribe.
For first time subscribers, our monthly payment starts at $1 + GST for the first month.
For first time subscribers, our monthly payment starts at $1 + GST for the first month.
Problems, questions, feedback? Please call +61 8 9288 2100
SUDA Pharmaceuticals (SUD)
Share Price
Closing price for the last 90 trading days
Source: Morningstar
Total Shareholder Return as at 29/03/18
1 year TSR | 5 year TSR | ||
---|---|---|---|
9th | Advance NanoTek | 1725% | 106% |
184th | Goldfields Money | 57% | 14% |
409th | WestStar Industrial | 3% | -51% |
642nd | SUDA Pharmaceuticals | -33% | -15% |
720th | Carnegie Clean Energy | -49% | 1% |
716 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar
Source: Morningstar
Share Transactions
Total value as at the date of the transaction
Source: Morningstar
Revenue
92nd | ![]() | SUDA Pharmaceuticals | $7.3m |
96th | ![]() | Carnegie Clean Energy | $5.3m |
97th | ![]() | Advance NanoTek | $5.1m |
100th | ![]() | WestStar Industrial | $4.6m |
101st | ![]() | Goldfields Money | $4.2m |
236 listed industrial companies ranked by revenue.
Source: Morningstar
Source: Morningstar
Remuneration from SUDA Pharmaceuticals
472nd | Stephen Carter | $279k |
477th | Joseph Ohayon | $277k |
Ranked by total remuneration from all listed WA companies
BNiQ Disclaimer
Some of the information on ASX-listed public companies is sourced from Morningstar Australasia Pty Ltd (ABN: 95 090 665 544).
It is important to note that the Morningstar information displayed by Business News is not to be copied or distributed except as authorised; and that such information is not warranted to be accurate, complete or timely and that neither Morningstar nor Business News are responsible for any damages or losses arising from any use of this information.
The information is general information only and does not constitute financial advice It is not intended to be, and should not be construed in any way as, investment, legal or financial advice
Retail clients should be advised the Morningstar Financial Services Guide can be found at http://www.morningstar.com.au/fsg.asp
Show moreIt is important to note that the Morningstar information displayed by Business News is not to be copied or distributed except as authorised; and that such information is not warranted to be accurate, complete or timely and that neither Morningstar nor Business News are responsible for any damages or losses arising from any use of this information.
The information is general information only and does not constitute financial advice It is not intended to be, and should not be construed in any way as, investment, legal or financial advice
Retail clients should be advised the Morningstar Financial Services Guide can be found at http://www.morningstar.com.au/fsg.asp
Add your comment